首页>投融资
Recce Pharmaceuticals
IPO后其他轮次
Recce Pharmaceuticals is an early-stage pharmaceutical company which is focused on the development of synthetic antibiotics for the treatment of antibiotic-resistant bacterial infections.In August 2023, Recce Pharmaceuticals Ltd received international cash receipt of A$98,428.27, a second rebate from the government of Canada as part of its Scientific Research and Experimental Development (SR&ED) tax incentive program.In April 2023, Recce Pharmaceuticals Ltd received additional non-dilutive funds from Radium Capital (Radium) for A$973,144 for Recces future research and development (R&D) tax incentive.In January 2023, Recce Pharmaceuticals Ltd received A$6.21 million from research and development rebate payments.In September 2020, Recce completes capital raising of $27.95 million.In April 2020, the company's securities would be placed in Trading Halt Session State at the request of the company, until the earlier of the commencement of normal trading on April 20, 2020
基本信息
-
公司全称Recce Pharmaceuticals Ltd
-
类型高分子抗生素开发商
-
产业领域药品研发/制造、研发制造服务、化学药
-
公司人数15人以下
-
地址Level 23,180 George St,Salesforce Tower Sydney 2000; AU; Telephone: +61292562571; Fax: +61280754584;
-
联系电话61 (2) 92562571
-
邮箱info@recce.com.au
-
成立时间2008-01-01
投融资
-
2023-04-06IPO后其他轮次64.78万美元Radium Capital
-
2023-04-06IPO后其他轮次64.78万美元Radium Capital
-
2020-09-29IPO后其他轮次1978万美元未透露
-
2020-09-29IPO后其他轮次1978万美元未透露
-
2016-01-15IPO未透露未透露
-
2016-01-15上市未透露未透露
- 加载更多
相关投融资企业
未公开
MISSION Therapeutics, founded in 2011 as a spin out from the University of Cambridge, focuses on the discovery and development of small molecules that target deubiquitinating enzymes, developed using DUB-Sphere, its proprietary DUB Drug Discovery Platform, to treat cancers and other diseases.In June 2020, the company its move to new purpose-built headquarters on the Babraham Research Campus, Cambridge, UK.In February 2016, the company raised GBP 60 million (US $85.77 million) including GBP 11.3 million (US $16.15 million) from Imperial Innovations Group with GBP 3.9 million (US $5.57 million) invested in the first tranche resulting in the Group's holding increased to 21.6% interest in the company,.In November 2013, the company received GBP 20 million (US $32.2 million) in a series B funding round, of which GBP $4.5 million (US $7.25 million) was funded by Imperial Innovations Group.In August 2011, the company received GBP 6 million (US $9.87 million) in funding
未公开
Abiliity Pharmaceuticals SL (fomerly AB Therapeutics), founded in November 2009 and headquartered in Spain, is a drug discovery and development company focussed on the development of therapeutics targeting cell membranes for cancer and other indications.In September 2012, the company planned for US facilities in Boston during 2013.In December 2018, the company closed a round of financing worth more than EUR 1,230,000 (US $1,398,300) through the crowdfunding platform Capital Cell . With the figure, the company exceeded the EUR 1 million (US $1.13) with which they had opened the campaign last September, and happened to be the largest round of Capital Cell.In September 2012, the company raised EUR 1 million (US $ 1.3 million) in a second financing round.By November 2010, the company had initiated a series A financing round; in April 2015, the series A financing round of EUR 10 million (US $10.98 million) was ongoing.In October 2020 AbilityPharma receives of t
增发
Larimar Therapeutics, Inc.是根据美国特拉华州法律于2005年11月22日注册成立。公司是一家生物制药公司，致力于显著改善因肥胖而影响身体健康的患者。 Beloranib是公司领先的候选产品，是一种新型的一级产品，用于多种适应症，包括肥胖和饮食过量的普拉德 - 威利综合症患者，与颅咽管瘤相关的肥胖，一般人群严重的母体肥胖等方面的治疗，该产品的用法是每周两次皮下注射。公司自成立以来，一直致力于研究和开发产品、招聘管理、收购经营性资产和筹集资金。因此，公司被认为是处于发展阶段。
浙公网安备33011002015279
本网站未发布麻醉药品、精神药品、医疗用毒性药品、放射性药品、戒毒药品和医疗机构制剂的产品信息